An International Study of Pembrolizumab for Drug-Resistant Gestational Trophoblastic Neoplasia

BACKGROUND: Data to guide use of anti-PD1 immunotherapy with pembrolizumab for gestational trophoblastic neoplasia (GTN) that is chemotherapy-resistant or in adjuvant settings are limited. We conducted an international retrospective study of pembrolizumab in GTN, including patients with ultra-high-risk choriocarcinoma and poor-prognosis placental site and epithelioid trophoblastic tumors (PSTT/ETT), with up to 8 years of follow-up. METHODS: We collected data on patients with GTN cases who received treatment with pembrolizumab between May 2015 and June 2023 from 20 centers in 16 countries. Cases were identified at Charing Cross Hospital, London; international centers with expertise in GTN were directly invited to identify and submit eligible cases treated during the study period. Clinical data were gathered from medical records using a standardized case-report form, curated centrally. Twenty-three samples were characterized by multiplex immunofluorescence, shallow whole-genome, and whole-transcriptome sequencing. RESULTS: We identified 76 patients with drug-resistant GTN treated with pembrolizumab. This included 60 (78.9%) patients with GTN and measurable disease. Complete response was achieved in 71.7% (n=43 of 60; 95% confidence interval [CI], 60.3 to 83.1). Two-year overall survival (OS) was 85.6% (95% CI, 76.7 to 95.4), with median follow-up from pembrolizumab initiation of 25.4 months (range, 1.4 to 95.7). Sixteen (21.1%) received adjuvant pembrolizumab instead of high-dose chemotherapy, of whom 15 had poor-prognosis PSTT/ETT. No deaths were observed with median follow-up of 33.1 months (range, 7.7 to 68.6) from first remission. There were no identified grade 4 or worse immune-related toxicities. On multiplex immunofluorescence, the median fluorescence intensity between-group difference in cancer cell HLA-G expression (responders minus nonresponders) was 0.6 (95% CI, 0.3 to 1.0). Shallow whole-genome and whole-transcriptome sequencing suggested low HLA-G expression could be due to transcriptional control. CONCLUSIONS: In this retrospective study without a control group, pembrolizumab was associated with durable responses in multidrug-resistant GTN and showed potential activity as adjuvant therapy for poor-prognosis PSTT/ETT. HLA-G expression warrants further exploration as a response biomarker. (Funded by Imperial College Experimental Cancer Medicine Centre and others.).

Authors

Institutions

Publication Details

Journal
NEJM Evidence
Published
2026-10-27
DOI
https://doi.org/10.1056/evidoa2600044
Citations
1
Primary Topic
Gestational Trophoblastic Disease Studies
Type
article
Field-Weighted Citation Impact
6.48
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An International Study of Pembrolizumab for Drug-Resistant Gestational Trophoblastic Neoplasia

Michael J. Seckl, Kevin Meyer Elias, Geoffrey J. Maher, Reece Caldwell et al.
1 citations
NEJM Evidence
Gestational Trophoblastic Disease Studies
6.48
article

An International Study of Pembrolizumab for Drug-Resistant Gestational Trophoblastic Neoplasia

Michael J. Seckl, Kevin Meyer Elias, Geoffrey J. Maher, Reece Caldwell, Jean‐Pierre Lotz, Ehsan Ghorani, Sook Ling Lai, Terry Tin, François Golfier, Khalid AbdulJabbar, Manuel Salto‐Tellez, Naveed Sarwar, Emily Jane Eleanor Rhydderch Hayes, Ulrika Joneborg, Benoît You, Touria Hajri, Matthew C. Winter, Ross Stuart Berkowitz, Pierre‐Adrien Bolze, Yujia Kong, Neil Stuart Horowitz, Emelie Wallin, Yang Xiang, Baljeet S. Kaur, Alexandra Ostler, Lara Ulrich, Tatiany Silveira, Tom Lund, Sevgi Bagislar Bremang
article en
1 citations

Abstract

BACKGROUND: Data to guide use of anti-PD1 immunotherapy with pembrolizumab for gestational trophoblastic neoplasia (GTN) that is chemotherapy-resistant or in adjuvant settings are limited. We conducted an international retrospective study of pembrolizumab in GTN, including patients with ultra-high-risk choriocarcinoma and poor-prognosis placental site and epithelioid trophoblastic tumors (PSTT/ETT), with up to 8 years of follow-up. METHODS: We collected data on patients with GTN cases who received treatment with pembrolizumab between May 2015 and June 2023 from 20 centers in 16 countries. Cases were identified at Charing Cross Hospital, London; international centers with expertise in GTN were directly invited to identify and submit eligible cases treated during the study period. Clinical data were gathered from medical records using a standardized case-report form, curated centrally. Twenty-three samples were characterized by multiplex immunofluorescence, shallow whole-genome, and whole-transcriptome sequencing. RESULTS: We identified 76 patients with drug-resistant GTN treated with pembrolizumab. This included 60 (78.9%) patients with GTN and measurable disease. Complete response was achieved in 71.7% (n=43 of 60; 95% confidence interval [CI], 60.3 to 83.1). Two-year overall survival (OS) was 85.6% (95% CI, 76.7 to 95.4), with median follow-up from pembrolizumab initiation of 25.4 months (range, 1.4 to 95.7). Sixteen (21.1%) received adjuvant pembrolizumab instead of high-dose chemotherapy, of whom 15 had poor-prognosis PSTT/ETT. No deaths were observed with median follow-up of 33.1 months (range, 7.7 to 68.6) from first remission. There were no identified grade 4 or worse immune-related toxicities. On multiplex immunofluorescence, the median fluorescence intensity between-group difference in cancer cell HLA-G expression (responders minus nonresponders) was 0.6 (95% CI, 0.3 to 1.0). Shallow whole-genome and whole-transcriptome sequencing suggested low HLA-G expression could be due to transcriptional control. CONCLUSIONS: In this retrospective study without a control group, pembrolizumab was associated with durable responses in multidrug-resistant GTN and showed potential activity as adjuvant therapy for poor-prognosis PSTT/ETT. HLA-G expression warrants further exploration as a response biomarker. (Funded by Imperial College Experimental Cancer Medicine Centre and others.).

NEJM EvidenceVol. 5(11)
Université Claude Bernard Lyon 1 (FR), Brigham and Women's Hospital (US), Royal Marsden NHS Foundation Trust (GB), Karolinska University Hospital (SE), Harvard University (US), Institute of Cancer Research (GB), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN), Charing Cross Hospital (GB), Weston Park Cancer Centre (GB), Karolinska Institutet (SE), Sorbonne Université (FR), London Cancer (GB), Assistance Publique – Hôpitaux de Paris (FR), Hospices Civils de Lyon (FR), Sheffield Teaching Hospitals NHS Foundation Trust (GB), North West London Pathology (GB), Dana-Farber Cancer Institute (US), Royal Marsden Hospital (GB), Dana-Farber/Harvard Cancer Center (US), Dana-Farber Brigham Cancer Center (US), Hôpital Tenon (FR), Centre pour l'innovation en cancérologie de Lyon (FR), Laboratoire d'hématologie (FR), Imperial College London (GB), University of Sheffield (GB)
Good health and well-being
Openalex Percentile: Top 3%
Gestational Trophoblastic Disease Studies
6.48
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon